Drug application
ZANTAC 150 (RANITIDINE HYDROCHLORIDE)
Drugs@FDA NDA 020251 · GLAXO GRP LTD
Key facts
| Drug name | ZANTAC 150 |
|---|---|
| Active ingredients | RANITIDINE HYDROCHLORIDE |
| Application type | NDA |
| Application number | 020251 |
| Company | GLAXO GRP LTD |
| Dosage forms | TABLET, EFFERVESCENT, ORAL |
| Strength | EQ 150MG BASE |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 3 - New Dosage Form |
| Latest submission status date | Mar 31, 1994 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: